[Whitepaper] ADC and Highly Potent Substance Containment

Solo Containment’s Martyn Ryder has been observing environmental monitoring systems from as early as 1989. It was clear from the start that segregation between operators and API powder was the key to reducing occupational exposure. In Ryder’s work, he grasped the importance of maintaining long-term and repeatable safety standards within the pharmaceutical sector.

As a leader in powder containment, ILC Dover has vast experience in the delivery and testing of flexible film isolator technology for hazardous API containment applications. With Solo Containment’s acquisition into the ILC Dover family, we can now bring in extensive front-end application risk and hazard assessment skills with a methodology for SOP development.

We developed the Full Lifecycle Safety structure to ensure customers can reap the benefits of the highest standards of long-term operator protection from single-use flexible film containment systems. In our most recent Webinar, we examined all aspects of pharmaceutical containment and revealed how ILC Dover works to implement safety assurance at every stage.

From the beginning of ADC and highly potent substance containment processes, we take client-generated data for containment performance targets and product toxicity data to set a HAZARD benchmark. We utilize this data to produce a Process Score and implement the correct standards for operator protection in even the most adverse situations. We follow these exact high-quality measures and comprehensive requirements through design, manufacturing, testing, and cleaning.

Learn more about ADC and HPAPI containment in our latest Whitepaper, and discover the eight stages of our Full Lifecycle Safety structure to see how we deliver the best possible containment solutions for any given application.

Ready to Go Beyond Boundaries® Together?

Tell us a little bit about your needs.